ProMab offers multiple cytokines response assays that provides accelerate cell and gene therapy-based immuno oncology (IO) drugs development and provides the analysis and assessment of the function of immune cells. The evaluation of cytokines releasing ability by those immune cells will be conducted with our unique platform.
The peptide antigens presented by antigen-presenting cells (APCs) will be designed, which will be recognized by T-cell receptors (TCRs). This recognition induces the activation of T-cells and a series of functional immune responses. The ability of cytokines releasing is an important parameter to evaluate the function as well as the efficiency of gene therapy-based IO drugs, such as the modified T cells transfer.
A reasonable range of cytokine release level is able to just activate T cells but not cause cytokine storm. ProMab’s platform provides standard methods to measure the effector cytokines responses, such as enzyme-linked immunospot assay (ELISpot) and intracellular cytokine staining assay (ICS) to detect the secretion of Interferon gamma (IFN-γ), Interleukin-2 (IL-2) and other cytokines. The Cytokine Response Assay can be also customized upon to your requirements in your IO drug development. Multiple analysis technology, instruments and various commercial ELISA assay kits are available with our platform.
Please contact us to discuss your needs or to request a quote.
Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. (2013). FDA DRAFT GUIDANCE, Clinical & Medical.